Nac Long

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nac Long

Quick Facts

  • Active Ingredient: Acetylcysteine (also known as N-Acetylcysteine or NAC)
  • Drug Class: Mucolytic Agent, Antidote
  • Form: Typically Effervescent Tablets or Sachets (Oral)
  • Status: Prescription or Over-the-Counter (Varies by country and indication)

Nac Long is a common brand name for a medication containing acetylcysteine, an amino acid derivative. Acetylcysteine is a globally recognized agent that plays two distinct and clinically significant roles in medicine.

Its primary and most critical use is as a specific antidote for acetaminophen (paracetamol) overdose. In this scenario, acetylcysteine works to maintain or replenish the body's stores of glutathione, a natural antioxidant essential for detoxifying the liver. Administered promptly, this action is highly effective in preventing or lessening severe liver damage that can result from acetaminophen toxicity.

Separately, acetylcysteine is classified as a mucolytic agent. This means it functions by reducing the thickness and stickiness (viscosity) of mucus secretions in the respiratory tract. A typical neutral use scenario for its mucolytic action is to help patients with conditions like acute or chronic bronchitis, or other disorders characterized by the production of excessive or thick, tenacious mucus, making it easier to cough up. This function involves a mechanism of action on the disulfide bonds within mucin proteins, thus breaking down the mucus.

Depending on the specific brand and local regulatory status, Nac Long is often supplied as effervescent tablets or powder for oral solution, which distinguishes its method of consumption. It is recognized that oral acetylcysteine has a low bioavailability; however, its effectiveness in both its antidote and mucolytic applications is strongly supported by decades of clinical practice and research.

Regulatory References

  1. World Health Organization Essential Medicines List (Acetylcysteine entry)
  2. N-Acetylcysteine - StatPearls - NCBI Bookshelf

What side effects are possible with Nac Long?

Official Safety Profile and Adverse Reactions

The safety profile for Nac Long (Acetylcysteine) is categorized by regulatory documents according to the frequency and system-organ class (SOC) of the reported adverse reactions.

Frequency-Classified Adverse Reactions

The most commonly listed adverse events are generally categorized as Uncommon, affecting between 1 in 100 to 1 in 1,000 users. These effects frequently involve the Gastrointestinal disorders (such as nausea, vomiting, abdominal pain, and diarrhea) and the Skin and subcutaneous tissue disorders (including rash, pruritus, and urticaria).

Reactions classified as Rare or Very Rare include more clinically significant, though highly infrequent, events. Rare events include bronchospasm and dyspnoea. Very Rare events, occurring in less than 1 in 10,000 users, include anaphylactic shock, severe anaphylactic/anaphylactoid reactions, and haemorrhage.

Serious Adverse Reactions and Constraints

The official safety labeling documents the risk of severe mucocutaneous reactions, such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), which have been reported in temporal association with acetylcysteine use.

Regulatory documents stipulate specific safety constraints. A known hypersensitivity to the active substance or its excipients is a formal contraindication. Caution is advised for individuals with bronchial asthma due to the potential risk of bronchospasm, and for patients with a history of peptic ulcer disease.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile of Nac Long (Acetylcysteine) by describing documented clinical manifestations and required emergency actions, based strictly on reports from excessively high ingestion or rapid administration.

Overdose manifestations typically fall into two categories:


Documented Overdose Presentations

Category Manifestations (as Labeled)
Gastrointestinal Nausea, Vomiting, Diarrhea, Dyspepsia
Cutaneous Flushing, Rash, Urticaria

Severe Systemic Outcomes & Emergency Action

Overdose may escalate to severe systemic effects requiring immediate medical intervention. These life-threatening outcomes include anaphylactoid reactions, severe hypotension (low blood pressure), bronchospasm (airway constriction), and angioedema.

Regulatory authorities mandate that any suspected overdose or the appearance of severe symptoms requires patients to seek immediate medical attention and contact emergency services immediately.

Official prescribing information states that no specific antidote is known for Acetylcysteine overdose. Consequently, treatment relies on symptomatic and supportive treatment and requires hospital monitoring to manage the manifestations effectively. Regulatory warnings also note an increased risk of severe reactions in patients with a history of asthma.

Therapeutic Uses of Nac Long

The therapeutic role of Nac Long (Acetylcysteine) is recognized across two distinct medical domains. The medication generally plays a dual role in supporting patient well-being during acute toxicity and chronic symptomatic conditions.

Emergency Treatment for Acetaminophen Toxicity

This application is relevant in clinical settings that involve acute or unstable symptom patterns related to potentially toxic ingestion of acetaminophen. It is commonly used as an emergency-use antidote to address the impending risk of severe organ-specific functional stress (hepatotoxicity). This provides support that helps ease the overall symptom burden by intervening, which may assist with support management of the severe physiological stress associated with hepatotoxicity in emergency poisoning scenarios.

Management of Respiratory Symptom Burden

Nac Long is commonly applied as a supportive treatment in respiratory medicine to manage symptoms of chronic conditions, including COPD, chronic bronchitis, and cystic fibrosis. It is used to address the symptomatic burden of excessively thick and sticky mucus by assisting the patient with the expectoration of these secretions, which provides support that contributes to improved comfort associated with impaired airway clearance. Furthermore, the drug may be part of symptomatic management applied during phases when symptoms that interfere with daily functioning become more noticeable, particularly during episodic flare-ups of chronic respiratory disorders.

Quick Fact: Therapeutic Use & Benefit
Primary Indication Areas: Acute toxic ingestion; conditions marked by tenacious or thick respiratory mucus.
Primary Benefit: Provides supportive relief when symptoms create noticeable physiological strain or discomfort.

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Nac Long (N-Acetylcysteine)

Official regulatory information defines specific populations who are excluded from using Nac Long or who require careful medical supervision.

Contraindications and Restrictions

Classification Regulatory Status
Absolute Contraindication Individuals with a known hypersensitivity or prior adverse reaction to acetylcysteine or any component of the formulation.
Conditions Requiring Caution Patients with a history of asthma or bronchospasm require close medical supervision due to the risk of inducing bronchospasm. Oral formulations require caution in patients with a history of peptic ulcers.
Age and Weight Use requires caution and careful monitoring in children and patients weighing less than 40 kg to manage the risk of fluid imbalance and seizures (especially with intravenous use).
Physiological Status Breastfeeding is not recommended due to unknown drug excretion into human milk. Use during pregnancy is advised only when the benefit clearly outweighs the potential risk.

Eligibility is also restricted for patients with severe renal or hepatic impairment due to altered drug clearance, necessitating conditional use and close monitoring.

What should I know about interactions with other medicines?

The official interaction profile for Nac Long (Acetylcysteine) is defined by regulatory authorities based on documented pharmacodynamic, pharmacokinetic, and chemical interaction patterns. These patterns establish mandatory restrictions on co-administration with other medicinal products and substances.

Documented Pharmacodynamic and Chemical Interactions

Interacting Substance/Class Official Interaction Outcome and Constraint
Antitussive Drugs Prohibited Co-administration (Pharmacodynamic Interference). The restriction is due to the potential for the reduced cough reflex to result in the retention and build-up of bronchial secretions.
Nitroglycerin (Nitrates) Augmented Vasodilatory Effects (Pharmacodynamic Augmentation). Concurrent use causes significant hypotension and may lead to headache due to temporal artery dilation. Monitoring for hypotension is required.
Oral Antibiotics Mandatory Time Separation (Chemical Incompatibility). Administration must be spaced by at least two hours before or after acetylcysteine to mitigate a degree of in vitro inactivation.

Exposure-Altering and Substance Restrictions

Interacting Substance/Product Regulatory Outcome
Activated Charcoal May reduce the effect/effectiveness of acetylcysteine due to a pharmacokinetic mechanism (altered absorption).
Carbamazepine Concurrent use may result in sub-therapeutic levels of Carbamazepine (reduced serum concentration).
Product Excipients Aspartame imposes a contraindication for Phenylketonuria. Sorbitol imposes a contraindication for hereditary fructose intolerance and may affect the bioavailability of other oral products.

These official statements structure the product's regulatory profile, defining mandatory administration sequences and prohibitions to manage the documented interaction risks.

Mechanism of Action

The pharmacological action of Acetylcysteine (Nac Long) is characterized by a unique dual mechanism, both relying on the chemical reactivity of its sulfhydryl ( -SH) group which drives distinct pharmacodynamic actions within the body.

Chemical Modification of Respiratory Secretions

This domain involves a direct chemical reduction where the sulfhydryl group of the molecule chemically cleaves the disulfide bonds ( S-S) that cross-link the large mucin proteins. This process of depolymerization drastically lowers the viscosity and elasticity of respiratory secretions, physiologically facilitating mucociliary transport by altering the viscoelastic properties of the secretions.

Action on Hepatic Redox Balance

Acetylcysteine acts as a crucial precursor by supplying L-cysteine, the rate-limiting amino acid for the synthesis of Glutathione (GSH). Replenishing these GSH stores is utilized by the liver for the conjugation and neutralization of highly reactive metabolites, a process which limits the progression of mitochondrial dysfunction and cellular damage resulting from accumulated toxins.

Dosage and Administration Information

Official Administration Guidelines for Acetylcysteine (Nac Long)

Nac Long (acetylcysteine) is officially administered via distinct protocols based on its two primary roles.

Administration Routes and Preparation

Usage Role Route & Form Standard Preparation Requirement
Mucolytic (Oral) Oral Powder/Granules Contents must be dissolved completely in a glass of water immediately before consumption.
Antidote (IV) Intravenous (IV) Infusion The concentrated solution must be diluted in designated IV fluids (e.g., 5% Glucose or 0.9% Sodium Chloride) prior to administration.
Mucolytic (Inhaled) Inhalation Solution (10% or 20%) May require dilution; often administered after an aerosolized bronchodilator is given.

Official Dosing and Regimens

1. Mucolytic Use (Oral):

The standard adult and adolescent dosage is typically 200 mg (one sachet) administered three times per day (TID). The total daily dose should not exceed 600 mg. The duration of therapy is not fixed and is determined by the chronic condition being addressed.

2. Antidote Use (Intravenous):

This application mandates a total dose of 300 mg/kg body weight, administered sequentially over a 21-hour period in three distinct infusions:

  • Phase 1 (Loading): 150 mg/kg infused over 1 hour.
  • Phase 2: 50 mg/kg infused over the next 4 hours.
  • Phase 3: 100 mg/kg infused over the final 16 hours.

Special Procedural Rules

  • Pediatric Dosing: For IV antidote treatment in patients under 40 kg, the total volume of diluent fluid is modified/reduced to avoid the risk of fluid overload, while the mg/kg dose remains the same.
  • Obese Patients: Dosage calculations for IV use are often capped at a ceiling weight (e.g., 110 kg), even if the patient's actual weight is higher.
  • Context: The IV regimen requires continuous administration in a supervised, critical-care setting, and treatment may be extended beyond 21 hours based on continued clinical need.

This structure ensures that the administration of Nac Long adheres to precise, standardized regulatory parameters for both self-administered and hospital-based use, without the inclusion of therapeutic claims or safety information.

Recent Clinical Evidence

Nac Long: Recent Clinical Evidence

Clinical research has focused on investigating the relationship between the active ingredient in Nac Long (N-acetylcysteine or NAC) and outcomes in various respiratory conditions, including Chronic Obstructive Pulmonary Disease (COPD), Chronic Bronchitis, and Cystic Fibrosis (CF). Studies have explored whether the compound's properties, which include its capacity to influence mucus viscosity, are associated with clinical changes.

Research Findings Overview

Research on the use of this compound in individuals with Chronic Bronchitis or COPD suggests mixed findings. Multiple meta-analyses have evaluated whether prolonged use may relate to a lower frequency of disease exacerbations. However, other large-scale randomized controlled trials (RCTs) involving patients with mild-to-moderate COPD did not observe a significant effect on the annual rate of exacerbations or lung function measures such as Forced Expiratory Volume in 1 second (FEV1).

Study Type Focus Area Key Outcome Evaluated
Meta-analysis Chronic Bronchitis / COPD Frequency of acute exacerbations
RCTs Mild-to-moderate COPD Annual rate of exacerbations and change in FEV1
Pilot Studies Cystic Fibrosis Effects on lung function decline over time

Duration and Dosage Research

Studies have investigated a wide range of dosages, generally between 600 mg/day and 1200 mg/day, sometimes for periods exceeding six months. Research suggests that a potential relationship between use and reduction in exacerbation rates may be more apparent with higher, prolonged daily dosages. Research has also explored the compound's tolerability profile across different durations of use, finding it to be generally well-tolerated in many long-term studies. Further research is ongoing to establish clearer evidence on the optimal duration and dosage for different patient populations.

Key Studies & References

  1. European Medicines Agency (EMA) Public Assessment Report (PAR) for N-acetylcysteine containing products (as representative regulatory document).

Frequently Asked Questions (FAQ)

Common questions about Nac Long (FAQ)

Q: How quickly do people typically notice an effect from Nac Long?

A: Official regulatory documents do not specify a standard time for an individual to notice a change. However, official pharmacokinetic data indicates that the maximum concentration of the active ingredient in the bloodstream is usually reached within 1 to 2 hours after it is consumed orally.


Q: Is Nac Long the same type of medicine as others used for coughs?

A: Nac Long is formally classified as a mucolytic agent. This means its core function is to work chemically to break down the structure of mucus to reduce its stickiness, a process that is distinct from the way other medicines like cough suppressants work to block the cough reflex.


Q: What is the recommended period of use for Nac Long?

A: The official duration of use for the mucolytic regimen is not fixed and is not standardized in the regulatory information. Official guidance indicates that the duration of therapy is related to the specific chronic condition being addressed.


Q: Can taking Nac Long cause nausea?

A: Yes, regulatory safety documents list nausea and vomiting among the commonly reported side effects. These effects frequently involve the gastrointestinal system, according to the official safety profile.


Q: Can I take Nac Long if I am also taking vitamins?

A: Official interaction profiles primarily list prescription medications and specific metal salts, such as iron and gold, that may be affected. There is no explicit general warning against all vitamins, but information about concurrent products and supplements is typically reviewed by a healthcare provider.


Q: Is there any research evidence supporting the use of Nac Long for respiratory symptoms?

A: Yes. The active ingredient in Nac Long is indicated in official documents for the treatment of airway diseases where the reduction of thick secretions is required, and research has specifically examined its effects in conditions like chronic bronchitis and COPD.


Q: Is Nac Long considered safe for long-term use?

A: Official documentation does not make generalized claims of 'safety' for prolonged use. However, evidence from long-term clinical studies, which have involved administration over periods exceeding several months, indicates the active ingredient is generally well-tolerated.


Q: Can older adults use Nac Long without special precautions?

A: Official product information advises that caution is specifically recommended for use in elderly or frail patients. This precaution is noted because an initial increase in bronchial secretions could complicate a pre-existing reduced ability to cough, and use in this population may be managed under medical supervision.


Q: Does Nac Long interact with blood pressure medications?

A: Yes, documented interactions exist with certain types of blood pressure medications. Official documents report that Nac Long can augment the vasodilatory effect of Nitroglycerin and may increase the blood pressure lowering effect of ACE inhibitors.


Q: Can a person who has stomach ulcers use Nac Long?

A: Official warnings state that caution is advised for patients who have a history of peptic ulcer disease. This is because the active ingredient may potentially have an undesirable effect on the gastric lining, and use in this population is typically managed with medical oversight.


Q: Does the time of day matter when using Nac Long?

A: Official administration guidelines specify the number of times the medicine should be used daily (e.g., three times per day). However, they do not specify a mandatory time of day (such as morning or night) for the standard mucolytic regimen.


Q: Are there different forms of Nac Long, like tablets versus powder?

A: Yes. The medicine is available in various forms depending on its intended use, which include oral options like effervescent tablets or powder/granules. It is also supplied as solutions prepared for intravenous (IV) administration or inhalation.


Q: What does 'expectorant' mean in relation to Nac Long?

A: Nac Long is classified as a mucolytic agent. This chemical action breaks down mucus and facilitates its expectoration—the process of coughing up secretions—which is a distinct mechanism from traditional medicines classified only as expectorants.


Q: What kind of research has been done on Nac Long's long-term safety?

A: Research on the active ingredient includes both large-scale randomized controlled trials (RCTs) and cohort studies that have investigated its tolerability. These studies have involved patient use over long periods, sometimes exceeding six months.


Q: Does Nac Long have any known effects on kidney function?

A: The use of the active ingredient in patients with severe renal impairment is subject to close medical monitoring due to altered drug clearance. The compound has also been the subject of research concerning its possible use in supporting kidney function.


Q: What is the difference between Nac Long and other forms of NAC (N-acetylcysteine)?

A: Nac Long is a brand name for a medicinal product whose active ingredient is N-acetylcysteine. According to authoritative sources, the terms NAC, N-acetyl-L-cysteine, and N-acetylcysteine all refer to the same active chemical compound.


Q: What is the official guidance regarding Nac Long use in people with liver problems?

A: The active ingredient is primarily used as an antidote to prevent severe liver damage. However, patients with severe hepatic impairment (liver problems) are typically subject to official caution and close medical monitoring due to altered drug clearance.


Q: Is there an age limit for using Nac Long, as per regulatory bodies?

A: Yes. Official documentation typically restricts the use of the oral mucolytic form to adults and adolescents over 12 years of age. Some specific formulations may also carry a contraindication for use in children under 2 years old.

How should Nac Long be stored and disposed of?

How to Store and Dispose of Nac Long (Acetylcysteine)

Official regulatory guidelines strictly define the necessary conditions for storing Nac Long oral formulations to maintain product integrity.

Storage and Handling

Condition Type Requirement
Temperature Range Store at a temperature not exceeding 25 C (77 F), generally within 20 C to 25 C.
Prohibited Environments Do not refrigerate or freeze the oral product.
Protection Keep the original container tightly closed to protect from moisture and store the sachet or blister in the outer carton to protect from light.
Stability Limit The solution prepared after dissolving the effervescent tablet must be used immediately.
Child Safety The medicine must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Nac Long must be disposed of according to local requirements. It must not be thrown away via wastewater or general household waste, aligning with environmental protection guidelines for medicinal products.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nac Long found in:

A-Z Index: